Trial site
Centre Hospitalier Regional Universitaire
Besancon Cedex, 25030, FranceNot linked to an institution yet
- 16running trials
- 4closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 29 trials
- Phase 35 trials
- Phase 2/34 trials
- Phase 42 trials
- Phase 1/21 trial
- Status
- Recruiting9 trials
- Completed4 trials
- Not yet recruiting4 trials
- Active, not recruiting3 trials
- Suspended1 trial
- Lead sponsor
- Centre Hospitalier Regional Universitaire3 trials
- Centre Hospitalier Universitaire de Besancon2 trials
- ALX Oncology Inc.1 trial
- Assistance Publique Hopitaux De Paris1 trial
- Bristol-Myers Squibb1 trial
- and 13 more
Running trials
Not yet recruiting
Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study.
NCT07883759· Phase 2· Centre Hospitalier Universitaire de Besancon· Source
Not yet recruiting
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Not yet recruiting
GLIFLOFASTER : EARLY GLIFLOZIN TREATMENT IN ELDERLY PATIENT HOSPITALIZED FOR DECOMPENSATED CHRONIC HEART FAILURE ADMITTED IN THE EMERGENCY ROOM - A FEASIBILITY STUDY
2025-521101-40-00· Phase 4· Centre Hospitalier Regional Universitaire· Source
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source
Not yet recruiting
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
NCT07347210· Phase 2· Centre Hospitalier Universitaire de Besancon· Source
Recruiting
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
NCT06245356· Phase 2· UNICANCER· Source
Recruiting
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· Phase 2· Centre Hospitalier Universitaire De Dijon· Source
Recruiting
REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer carcinoma
2024-516709-22-00· Phase 2/3· Centre Hospitalier Regional Universitaire· Source
Recruiting
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) on progression-free survival compared with standard Regorafenib for the treatment of chemo-resistant metastatic colorectal cancers
2023-509761-21-00· Phase 3· Centre Hospitalier Regional Universitaire· Source
Recruiting
Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
NCT05674994· Phase 3· Fondation Hôpital Saint-Joseph· Source
Active, not recruiting
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
NCT05346848· Phase 2· Institut Bergonié· Source
Recruiting
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
NCT05384821· Phase 1/2· Centre Oscar Lambret· Source
Recruiting
TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis
NCT03910738· Phase 2· University Hospital, Strasbourg, France· Source
Recruiting
Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole
NCT03656081· Phase 3· Poitiers University Hospital· Source
Active, not recruiting
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
NCT02066220· Phase 2/3· Universitätsklinikum Hamburg-Eppendorf· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error